C-X-C Chemokine Receptor Type 4 - Pipeline Review, H1 2019
C-X-C Chemokine Receptor Type 4 - Pipeline Review, H1 2019
SUMMARY
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - C-X-C chemokine receptor type 4 or CD184 is a protein encoded by the CXCR4 gene. It is a receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation, extracellular ubiquitin, leading to enhanced intracellular calcium ions and reduced cellular cAMP levels. It is involved in hematopoiesis and in cardiac ventricular septum formation. It also plays an essential role in vascularization of the gastrointestinal tract, probably by regulating vascular branching and/or remodeling processes in endothelial cells.
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) pipeline Target constitutes close to 27 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 5, 3, 1, 11 and 1 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.
Report covers products from therapy areas Oncology, Cardiovascular, Genetic Disorders, Hematological Disorders, Immunology, Central Nervous System, Gastrointestinal, Genito Urinary System And Sex Hormones, Infectious Disease, Male Health, Ophthalmology, Respiratory and Undisclosed which include indications Multiple Myeloma (Kahler Disease), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Melanoma, Non-Hodgkin Lymphoma, Pancreatic Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Breast Cancer, Colon Cancer, Neuroblastoma, Prostate Cancer, Solid Tumor, Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Aplastic Anemia, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Critical Limb Ischemia, Epithelial Ovarian Cancer, Erectile Dysfunction, Gastric Cancer, Glioblastoma Multiforme (GBM), Hematopoietic Stem Cell Transplantation, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Human Immunodeficiency Virus (HIV) Infections (AIDS), Idiopathic Pulmonary Fibrosis, Inflammation, Intimal Hyperplasia, Kidney Fibrosis, Liver Cancer, Lung Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Myelodysplastic Syndrome, Myocardial Infarction, Neutropenia, Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Osteosarcoma, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Primary Immune Deficiency (PID), Recurrent Glioblastoma Multiforme (GBM), Renal Cell Carcinoma, Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Stroke, Thrombocytopenia, Unspecified, Vasomotor Symptoms (Non-Menopausal), Wet (Neovascular/Exudative) Macular Degeneration, WHIM Syndrome (Warts, Hypogammaglobulinemia and Infections and Myelokathexis).
The latest report C-X-C Chemokine Receptor Type 4 - Pipeline Review, H1 2019, outlays comprehensive information on the C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - C-X-C chemokine receptor type 4 or CD184 is a protein encoded by the CXCR4 gene. It is a receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation, extracellular ubiquitin, leading to enhanced intracellular calcium ions and reduced cellular cAMP levels. It is involved in hematopoiesis and in cardiac ventricular septum formation. It also plays an essential role in vascularization of the gastrointestinal tract, probably by regulating vascular branching and/or remodeling processes in endothelial cells.
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) pipeline Target constitutes close to 27 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 5, 3, 1, 11 and 1 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.
Report covers products from therapy areas Oncology, Cardiovascular, Genetic Disorders, Hematological Disorders, Immunology, Central Nervous System, Gastrointestinal, Genito Urinary System And Sex Hormones, Infectious Disease, Male Health, Ophthalmology, Respiratory and Undisclosed which include indications Multiple Myeloma (Kahler Disease), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Melanoma, Non-Hodgkin Lymphoma, Pancreatic Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Breast Cancer, Colon Cancer, Neuroblastoma, Prostate Cancer, Solid Tumor, Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Aplastic Anemia, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Critical Limb Ischemia, Epithelial Ovarian Cancer, Erectile Dysfunction, Gastric Cancer, Glioblastoma Multiforme (GBM), Hematopoietic Stem Cell Transplantation, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Human Immunodeficiency Virus (HIV) Infections (AIDS), Idiopathic Pulmonary Fibrosis, Inflammation, Intimal Hyperplasia, Kidney Fibrosis, Liver Cancer, Lung Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Myelodysplastic Syndrome, Myocardial Infarction, Neutropenia, Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Osteosarcoma, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Primary Immune Deficiency (PID), Recurrent Glioblastoma Multiforme (GBM), Renal Cell Carcinoma, Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Stroke, Thrombocytopenia, Unspecified, Vasomotor Symptoms (Non-Menopausal), Wet (Neovascular/Exudative) Macular Degeneration, WHIM Syndrome (Warts, Hypogammaglobulinemia and Infections and Myelokathexis).
The latest report C-X-C Chemokine Receptor Type 4 - Pipeline Review, H1 2019, outlays comprehensive information on the C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)
- The report reviews C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics and enlists all their major and minor projects
- The report assesses C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Overview
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Companies Involved in Therapeutics Development
AdAlta Ltd
Ambrx Inc
Biokine Therapeutics Ltd
BioLineRx Ltd
Bristol-Myers Squibb Co
Eli Lilly and Co
FairJourney Biologics SA
GlycoMimetics Inc
Pfizer Inc
Polyphor AG
Tactiva Therapeutics LLC
TaiGen Biotechnology Co Ltd
Upsher-Smith Laboratories Inc
X4 Pharmaceuticals Inc
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Drug Profiles
AD-214 - Drug Profile
AM-3114 - Drug Profile
balixafortide - Drug Profile
BKT-300 - Drug Profile
BL-8040 - Drug Profile
burixafor - Drug Profile
GMI-1359 - Drug Profile
HPH-112 - Drug Profile
hz-515H7 - Drug Profile
LY-2510924 - Drug Profile
mavorixafor - Drug Profile
Monoclonal Antibodies to Antagonize CXCR4 for Unspecified Indication - Drug Profile
Monoclonal Antibody Conjugate to Antagonize CXCR4 for Oncology - Drug Profile
Oncolytic Virus to Antagonize CXCR4 for Oncology - Drug Profile
PF-06747143 - Drug Profile
POL-5551 - Drug Profile
Protein to Agonize CXCR4 for Inflammation - Drug Profile
PTX-9908 - Drug Profile
Q-122 - Drug Profile
Recombinant Protein to Agonize CXCR4 for Erectile Dysfunction - Drug Profile
Recombinant Protein to Antagonize CXCR4 for Oncology - Drug Profile
Small Molecule to Antagonize CXCR4 for Oncology - Drug Profile
ulocuplumab - Drug Profile
USL-311 - Drug Profile
X-4P002 - Drug Profile
X-4P003 - Drug Profile
X4-136 - Drug Profile
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Dormant Products
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Discontinued Products
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Overview
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Companies Involved in Therapeutics Development
AdAlta Ltd
Ambrx Inc
Biokine Therapeutics Ltd
BioLineRx Ltd
Bristol-Myers Squibb Co
Eli Lilly and Co
FairJourney Biologics SA
GlycoMimetics Inc
Pfizer Inc
Polyphor AG
Tactiva Therapeutics LLC
TaiGen Biotechnology Co Ltd
Upsher-Smith Laboratories Inc
X4 Pharmaceuticals Inc
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Drug Profiles
AD-214 - Drug Profile
AM-3114 - Drug Profile
balixafortide - Drug Profile
BKT-300 - Drug Profile
BL-8040 - Drug Profile
burixafor - Drug Profile
GMI-1359 - Drug Profile
HPH-112 - Drug Profile
hz-515H7 - Drug Profile
LY-2510924 - Drug Profile
mavorixafor - Drug Profile
Monoclonal Antibodies to Antagonize CXCR4 for Unspecified Indication - Drug Profile
Monoclonal Antibody Conjugate to Antagonize CXCR4 for Oncology - Drug Profile
Oncolytic Virus to Antagonize CXCR4 for Oncology - Drug Profile
PF-06747143 - Drug Profile
POL-5551 - Drug Profile
Protein to Agonize CXCR4 for Inflammation - Drug Profile
PTX-9908 - Drug Profile
Q-122 - Drug Profile
Recombinant Protein to Agonize CXCR4 for Erectile Dysfunction - Drug Profile
Recombinant Protein to Antagonize CXCR4 for Oncology - Drug Profile
Small Molecule to Antagonize CXCR4 for Oncology - Drug Profile
ulocuplumab - Drug Profile
USL-311 - Drug Profile
X-4P002 - Drug Profile
X-4P003 - Drug Profile
X4-136 - Drug Profile
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Dormant Products
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Discontinued Products
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by AdAlta Ltd, H1 2019
Pipeline by Ambrx Inc, H1 2019
Pipeline by Biokine Therapeutics Ltd, H1 2019
Pipeline by BioLineRx Ltd, H1 2019
Pipeline by Bristol-Myers Squibb Co, H1 2019
Pipeline by Eli Lilly and Co, H1 2019
Pipeline by FairJourney Biologics SA, H1 2019
Pipeline by GlycoMimetics Inc, H1 2019
Pipeline by Harmonic Pharma, H1 2019
Pipeline by Pfizer Inc, H1 2019
Pipeline by Polyphor AG, H1 2019
Pipeline by Que Oncology Inc, H1 2019
Pipeline by Tactiva Therapeutics LLC, H1 2019
Pipeline by TaiGen Biotechnology Co Ltd, H1 2019
Pipeline by Upsher-Smith Laboratories Inc, H1 2019
Pipeline by X4 Pharmaceuticals Inc, H1 2019
Dormant Products, H1 2019
Discontinued Products, H1 2019
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by AdAlta Ltd, H1 2019
Pipeline by Ambrx Inc, H1 2019
Pipeline by Biokine Therapeutics Ltd, H1 2019
Pipeline by BioLineRx Ltd, H1 2019
Pipeline by Bristol-Myers Squibb Co, H1 2019
Pipeline by Eli Lilly and Co, H1 2019
Pipeline by FairJourney Biologics SA, H1 2019
Pipeline by GlycoMimetics Inc, H1 2019
Pipeline by Harmonic Pharma, H1 2019
Pipeline by Pfizer Inc, H1 2019
Pipeline by Polyphor AG, H1 2019
Pipeline by Que Oncology Inc, H1 2019
Pipeline by Tactiva Therapeutics LLC, H1 2019
Pipeline by TaiGen Biotechnology Co Ltd, H1 2019
Pipeline by Upsher-Smith Laboratories Inc, H1 2019
Pipeline by X4 Pharmaceuticals Inc, H1 2019
Dormant Products, H1 2019
Discontinued Products, H1 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Top 10 Routes of Administration, H1 2019
Number of Products by Stage and Top 10 Routes of Administration, H1 2019
Number of Products by Top 10 Molecule Types, H1 2019
Number of Products by Stage and Top 10 Molecule Types, H1 2019
COMPANIES MENTIONED
AdAlta Ltd
Ambrx Inc
Biokine Therapeutics Ltd
BioLineRx Ltd
Bristol-Myers Squibb Co
Eli Lilly and Co
FairJourney Biologics SA
GlycoMimetics Inc
Harmonic Pharma
Pfizer Inc
Polyphor AG
Que Oncology Inc
Tactiva Therapeutics LLC
TaiGen Biotechnology Co Ltd
Upsher-Smith Laboratories Inc
X4 Pharmaceuticals Inc
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Top 10 Routes of Administration, H1 2019
Number of Products by Stage and Top 10 Routes of Administration, H1 2019
Number of Products by Top 10 Molecule Types, H1 2019
Number of Products by Stage and Top 10 Molecule Types, H1 2019
COMPANIES MENTIONED
AdAlta Ltd
Ambrx Inc
Biokine Therapeutics Ltd
BioLineRx Ltd
Bristol-Myers Squibb Co
Eli Lilly and Co
FairJourney Biologics SA
GlycoMimetics Inc
Harmonic Pharma
Pfizer Inc
Polyphor AG
Que Oncology Inc
Tactiva Therapeutics LLC
TaiGen Biotechnology Co Ltd
Upsher-Smith Laboratories Inc
X4 Pharmaceuticals Inc
